Powering an Evolution takes experience

Sigal is the CEO and Co-Founder of Starget Pharma. Sigal is a seasoned executive manager and a serial entrepreneur. She brings extensive business and management experience in global companies and startups. Sigal was the VP of Marketing, Strategy, and Business Operations at Microsoft Israel, leading the P&L and go-to-market for all Microsoft products in Israel. Before Starget Pharma, Sigal was a co-founder and investor in several technology startup companies. Sigal also held leadership positions of VP of Strategic Marketing, Head of Products, and Director of Corporate Business Development and M&A at Comverse, a global telecom solutions provider. In the past, Sigal worked as a strategy consultant at Shaldor, advising the top management of global pharma and hi-tech companies on product strategy and M&A. In the past, Sigal was named one of the 40 most promising Israeli managers under 40 by Globes magazine. Sigal holds an Executive MBA from Kellogg Northwestern University and Tel-Aviv University and BA in computer science and economics from Reichman University and Tel-Aviv University, respectively.

Michel is the Head of Drug Development at Starget Pharma. Michel is a seasoned drug discovery and development executive with over 25 years of experience. He has vast expertise in peptide-based drugs including medicinal chemistry, molecular biology, pharmacology, IND regulations, and pharmaceutical sciences. He was previously the Head of Pharmacology R&D at Peptor, an inventor of the phase 3 novel somatostatin analog Somatoprim® for metabolic disorders, and NET and co-inventor of the backbone-cyclization patents portfolio. He co-founded the consortium “pharmalogica” for early prediction models in drug discovery and development. He has also developed innovative, nanomedicine-based drug delivery systems and precision oncology of molecular targeting drug candidates. Michel has led multiple drug development programs resulting in IND fillings and clinical trials. Michel is a leading lecturer of pharmaceutical sciences and advanced drug delivery systems at the School of Pharmacy, Hebrew University, Israel, and serves as the head of the pharmaceutical industry in the Israeli national pharmacy council. He holds a B.Sc. in Life Sciences, M.Sc. studies in Molecular Biology, B. Pharm (License) in Pharmacy., M.Sc. Pharm., and a Ph.D. at the faculties of medicine, mathematics, and life-sciences of the Hebrew University.

Mor is the Head of Research & Development at Starget Pharma. Mor is a highly experienced medical scientist and R&D project manager with over 30 years of experience in biopharmaceutical developments for the diagnostics and therapy of cancer. Before Starget Pharma, she led a wide range of exploratory oncology projects, as a senior scientist and R&D project manager, at the Advanced Technology Center (ATC), Sheba Medical Center, Israel. Before Sheba medical center, Mor was a researcher in the immunohistochemistry developments laboratories at Interpharm (Serono/Merck), Israel. She is the co-inventor of novel series of conjugated backbone-cyclic somatostatin analogs for cancer targeting, representing the core IP of Starget Pharma proprietary platform technology. She co-authored numerous scientific publications and won the Wolf Foundation award for Ph.D. excellence. Mor has a Ph.D. degree in medical sciences from Sackler Faculty of Medicine at Tel Aviv University and an MBA from Bar-Ilan University, Israel.

Sagit is the Head of Medicinal Chemistry at Starget Pharma. Sagit has extensive experience in innovative medicinal chemistry. She led a range of research and developments projects in the biopharmaceutical and pharmaceutical industry. Sagit is specializing in peptides medicinal chemistry design and developments and in the chemistry of solid-phase peptide synthesis. Prior to Starget Pharma, Sagit served as an R&D chemist in global pharmaceutical companies including Abbvie and Teva Pharmaceutical, She focused on API scalability and developments of polymers-based drug delivery and devices. She was responsible for developments of innovative methods and leading chemistry R&D and scale-up processes and played a key CMC role in the submission of new products to the FDA. She is a co-inventor of novel pharmaceutical formulations and scaleup processes. She has a Ph.D. degree in chemistry from Bar-Ilan University, Israel.

Yoseph is the Head of Chemistry at Starget Pharma. Yoseph is a senior expert in peptides chemistry. He has over 40+ years of experience in the biopharmaceutical industry in organic and bioorganic chemistry. He is a co-author and co-inventor in the design and synthesis of novel imaging and therapeutic agents for cancer, including peptides, peptidomimetics, nanoparticles, and radiopharmaceutical ligands. Before Starget, Yoseph was a senior chemist in innovative biopharmaceutical startups, including Peptor, Develogen, Steba Laboratories, and Salio. He is the co-inventor of a novel series of conjugated backbone-cyclic somatostatin analogs for cancer targeting, representing the core IP of Starget Pharma proprietary platform technology. He holds ten registered patents in peptide and peptidomimetic chemistry, and he is a co-author of dozens of scientific publications in peptide medicinal chemistry. He has a Ph.D. in organic and bioorganic chemistry from Moscow State University.

Professor Chaim Gilon (Professor Emeritus Active) is a worldwide pioneer of solid phase peptide synthesis (SPPS) and the inventor of the backbone cyclization platform technology of peptide-based drug development. Prof. Gilon graduated with his academic degrees in chemistry and biochemistry at the Hebrew University, Jerusalem, Israel (HUJI), in 1965. Three years later, he earned a Ph.D. degree in organic chemistry from the Hebrew University. He then pursued post-doctoral studies at the University of California, San Diego, USA, and was a research associate in the Nobel laurite Roger Guillemin’s group at Salk Institute San Diego, CA, USA as an expert in SPPS. Since 1987, he has been a full Professor, including head of the organic chemistry department at HUJI Hebrew University, Israel, and visiting professor at the Peptide Institute, Osaka, Japan. Prof. Gilon research and developments in peptide chemistry have been granted as patents worldwide and recognized by several awards, including the Kaye Innovation Award, HUJI, Bergman Award, National Academy of Sciences Israel, and Humboldt Award, Government of Germany. Prof. Gilon is Co-Founder and Vice President of the Israeli Combichem Society and a senior consultant in peptide chemistry in the innovative peptide-based drugs industry.

Arie is the director of the Advanced Technology Center at the Sheba Medical Center and a Clinical Director at Starget Pharma. Arie is a renowned expert in the field of medical laser applications and Photodynamic Therapy (PDT) for skin cancer. As the founder and director of the Advanced Technology Center (ATC) at the Sheba Medical Center, Arie has brought together a diverse group of professionals, including clinicians, scientists, academics, and industry representatives, to work toward the development of innovative diagnostic and therapeutic technologies and he is one of the inventors of the original technology of Starget Pharma. Before his role at the ATC, Arie served as the Director of the Sheba Medical Center Department of Plastic and Reconstructive Surgery and Burns. He has held leadership positions in the medical community, including serving as Co-Chairman of the Israel Medical Association for 12 years and as the Israeli representative on the board of the World Medical Association for 15 years. Arie has published hundreds of scientific papers and holds several patents. He obtained his MD from Tel Aviv University.

Ronen is the Chairman and Co-Founder of Starget Pharma. Ronen is a serial entrepreneur and angel investor in pharma and tech companies with a successful track record as a Co-Founder and Board Member of Urogen Pharma Ltd. (IPO on Nasdaq) developing novel solutions for urologic cancers. Ronen was also CEO and Co-Founder of Infiapps Ltd, Chairman, and Co-Founder of several tech companies, and angel investor and board member at several startups. In the past, Ronen served as the Director of Private Equity & Alternative Investments Group at CMS Companies, a US financial services firm managing more than $3 billion in client assets. He holds an MBA from Kellogg, Northwestern University and a BA in Economics and Management from Tel Aviv University, with distinction.